P. Poikonen

Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area.

C. Blomqvist, H. Joensuu, P. Poikonen, 2001, Acta oncologica.

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF

C. Blomqvist, H. Joensuu, J. Lundin, 1999, British Journal of Cancer.

Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel

C. Blomqvist, H. Joensuu, S. Klaar, 2004, Acta oncologica.

Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer

C. Blomqvist, R. Amini, C Blomqvist, 2005, British Journal of Cancer.

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.

V. Kataja, A. Jukkola-Vuorinen, H. Joensuu, 2009, The Lancet. Oncology.

Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.

V. Kataja, A. Jukkola-Vuorinen, H. Joensuu, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients.

C. Blomqvist, H. Joensuu, T. Saarto, 2000, European journal of cancer.